Skip to main content
v2026.11,986 entries · CC-BY 4.0

DCTP (CASRAI)

Decentralized Clinical Trials Certification (DCTP)

Examined Professional credential on running trials with decentralised elements under ICH E6(R3) Annex 2: remote consent, home visits, direct-to-participant IMP, DHTs and data oversight.

LevelProfessionalDCTDCTP (CASRAI)
6 h
Nominal
Self-paced study
12
Lessons
Self-paced
8
Domains
Exam blueprint
75
Exam items
Per attempt
70%
Pass mark
Fixed, uncurved
90
Retake wait
Days
3 yr
Valid for
From the pass

What you earn

The credential itself

Pass the examination and CASRAI issues this certificate and the post-nominal DCTP (CASRAI), signed by the Programme Director, valid for 3 years, and checkable by anyone from the verification code on its face.

Specimen. Issued as a signed PDF and as a machine-readable Open Badge; the holder and code shown are illustrative.
How it appears on your CV

Certifications

DCTP (CASRAI) — Decentralised & Digital Trials, Professional

CASRAI·Issued Mar 2026·Credential ID CASRAI-DCT-2026-8N9UTR

casrai.org/verify/CASRAI-DCT-2026-8N9UTR

Every certificate is issued under the signature of Dr. Diana Nieves Castro, MD, Programme Director of CASRAI Certification, who sets the syllabus, blueprint and pass mark for this credential.

It certifies that its holder passed the CASRAI examination for this course on the date shown, scored against the blueprint and pass mark published on this page — and anyone can confirm it from the verification code, without an account and without contacting us.

About this credential

What it covers

Who this course is for

Decentralised and Digital Trials – Professional (DCTP) is for people who design, approve, run or check clinical trials in which some activities happen away from the investigator’s site: at the participant’s home, at a local healthcare centre or mobile unit, by video call, or through apps, wearables and sensors. It suits clinical trial managers and study leads at sponsors and CROs, site and network operations leads, clinical research coordinators and research nurses on hybrid studies, regulatory affairs and start-up staff, GCP quality assurance and audit staff, digital health and data teams bringing devices and ePRO into trials, vendor-oversight staff, and ethics committee members and administrators.

It assumes you already know how a conventional trial works under ICH E6(R3): what consent, investigator responsibility, investigational product accountability and source records mean. The course teaches what changes when an activity moves away from the site. It is a research operations, oversight and governance course. It does not teach clinical skills such as nursing technique, physical assessment by video or interpreting a biomarker.

What you will be able to do

  • Classify every activity in a protocol as at, or away from, the investigator’s location, and tell decentralised elements, pragmatic elements and real-world data apart, as ICH E6(R3) Annex 2 defines them.
  • Locate the governing provision for a described situation in the E6(R3) Principles, Annex 1 or Annex 2, and state which instrument applied on a given date in the EU, the UK or the US.
  • Write the protocol description and justification of a decentralised element, and prepare what an ethics committee needs to evaluate it.
  • Design a remote consent process: identity assurance, pre-specified verification and privacy safeguards, a paper or in-person alternative, and disclosure of who will see the participant’s address and health records.
  • Set proportionate investigator oversight for remote visits, home nursing, mobile units and local healthcare professionals, and keep the investigator’s decisions with the investigator when the sponsor contracts the provider.
  • Assess whether an investigational product can be shipped directly to participants, and design authorisation, accountability, blinding protection and privacy into the supply chain.
  • Treat a wearable, app or ePRO system as a data acquisition tool: fitness for purpose, validation, metadata, control of data and timely investigator access.
  • Map data flow and source records across several systems and providers, scope sponsor access to real-world data by criticality, and set up remote read-only monitoring access properly.
  • Assess privacy disclosures, breach risk and equity in both directions, recognise licensure and cross-border questions, and run a proportionate risk assessment of decentralised elements, including recommending against an element that is not justified.

The modules

  1. What “decentralised” means. Why ICH counts activities, not trials; decentralised elements, pragmatic elements and real-world data; the spectrum from site-based to fully remote.
  2. ICH E6(R3) Annex 2, section by section. Its structure, its status and dates, how it relates to the Principles and Annex 1, and the proportionate risk-based approach that runs through it.
  3. Jurisdictions, the protocol and the ethics committee. The EU Clinical Trials Regulation, the amended UK clinical trials regulations, the two final FDA guidances, the decentralised-manufacture trap, and what the protocol and the ethics submission must contain.
  4. Remote consent and eConsent. Identity assurance, the paper or in-person option, disclosure of who receives personal information, consent for real-world data, and eConsent as a computerised system.
  5. Remote visits and investigator oversight. Choosing a level of oversight, healthcare professionals working in usual clinical practice, certified copies, and documenting telehealth visits.
  6. Home nursing, mobile units and service providers. Who decides and who oversees when the sponsor arranges a provider, safety information from home visits, and provider assessment.
  7. Direct-to-participant investigational product. Investigator- and sponsor-arranged shipment, authorisation, product suitability, accountability, returns and blinding.
  8. Digital health technologies and digital endpoints. DHTs as data acquisition tools, source data from sensors, validation questions, alerts, and changes made by vendors mid-study.
  9. ePRO and eCOA. Instrument selection, moving an instrument from paper to screen, diary design, ePRO as source, and investigator access without unblinding.
  10. Data flow, remote source access and oversight. Source records across several originators, real-world data access by criticality, data linkage, security, remote monitoring and multi-provider oversight.
  11. Privacy, equity and jurisdiction. Disclosure to service providers, breach risk, pseudonymised data, equity in both directions, and licensure across borders.
  12. Risk assessment and integrated case. A proportionate risk assessment of decentralised elements, and a worked case that brings the whole course together.

About ICH E6(R3) Annex 2

Annex 2 is the part of the ICH Good Clinical Practice guideline that covers decentralised elements, pragmatic elements and real-world data. It reached ICH Step 4 on 3 June 2026, and its date for coming into effect in the EU is 15 January 2027. The course teaches Annex 2 with that status stated, alongside the E6(R3) Principles and Annex 1, which took effect in the EU on 23 July 2025. The course and the exam question bank are reviewed when Annex 2 comes into effect.

The exam

  • 75 scored multiple-choice questions, each with four options, drawn from a larger question bank in proportion to the eight exam domains. The order of options changes between attempts.
  • Most questions are short scenarios that ask you to apply or analyse a provision rather than recall it.
  • Pass mark: 70%.
  • You must finish the exam within 4 hours of starting it.
  • You must complete all lessons before you can start the exam.
  • If you do not pass, you can retake the exam after 90 days.

Eligibility

DCTP has a single Professional tier; there is no Foundation tier for this subject. You need working knowledge of ICH E6(R3) Principles and Annex 1, shown by one of: a CASRAI Good Clinical Practice credential; a GCP training certificate dated after 23 July 2025, or one that otherwise covers E6(R3); or a current ACRP, SOCRA or SCDM credential whose scope includes GCP. You also need to meet one of four experience routes:

  • Practice route: 24 months’ clinical research experience in the last six years in an operations, site, monitoring, regulatory, quality, data or oversight role.
  • Site route: 24 months in any research-facing role at an investigator site, academic trial unit, hospital research office or site network.
  • Stacking route: a CASRAI clinical-track Professional credential plus 12 months’ clinical research experience.
  • Ethics committee route: 24 months as a member or administrator of an IRB, IEC or research ethics committee.

Experience of decentralised trials is not required. You confirm at checkout that you meet the knowledge requirement and one route; no documents are requested.

What the credential is, and what it is not

DCTP (CASRAI) is an examined credential issued by CASRAI. Passing the exam earns a certificate that others can verify with CASRAI, showing the date you passed.

It is not accredited by any accreditation body. It carries no continuing education credit (CE, CME or CEU). It does not satisfy any statutory, regulatory, sponsor, funder or institutional training requirement, and it is not endorsed by ICH, any regulator such as EMA, MHRA or FDA, any ethics committee, or any professional body. It attests to competence in research operations, oversight and governance only: it is not a clinical qualification and does not qualify you to perform, supervise or direct any clinical activity, including home administration of investigational product or remote clinical assessment. It is not a licence and gives you no authority to approve or waive anything, and it is not equivalent to any other organisation’s credential.

Validity and renewal

The certificate is valid for three years from the date you pass. To renew it, you pass the current version of the exam again before it expires. Course access is a one-off purchase and does not expire.

Body of knowledge

Exam blueprint

The exam is assembled to these weights on every attempt. They are published before purchase because a blueprint you cannot see is not a blueprint.

Domains and weights8 domains · 75 scored items
DomainWeight
Decentralisation concepts, the spectrum, and feasibility assessmentD1
10%8 items
Regulatory framework for decentralised elementsD2
16%12 items
Informed consent obtained remotely, and eConsent designD3
12%9 items
Remote visits, local healthcare settings, home nursing and mobile unitsD4
12%9 items
Direct-to-participant investigational product supply and accountabilityD5
12%9 items
Digital health technologies, digital endpoints and eCOAD6
15%11 items
Data flow, remote source access, and oversight architectureD7
13%10 items
Privacy, equity, jurisdiction and risk assessmentD8
10%7 items
Total100%

Every attempt has this many items from each domain. The items themselves are drawn at random from the bank within those fixed per-domain quotas, so no two attempts are the same paper.

Syllabus

Syllabus: 12 lessons, 6 hours

Every lesson and every learning outcome is listed. The lesson bodies open on enrolment, and the exam opens once every lesson is marked complete.

12 lessons · 6 h

Lesson material opens once you are enrolled. The full syllabus and every learning outcome are shown here so you can judge the coverage before you pay.

  1. Lesson 1

    Module 1

    1 lesson · 30 min

    1. Locked.What “decentralised” means: elements, not trials30 min · Locked

      On completion you will be able to

      • State the Annex 2 definitions of decentralised elements, DHTs, pragmatic elements and RWD and explain why they are framed around activities
      • Classify each activity in a supplied protocol as at, or outside, the investigator's location
      • Identify which of the three methodologies a design contains and distinguish primary collection from secondary use
      • Place a design on the site-based to fully remote spectrum and justify the placement
      • Explain why a trial-level label does not settle any oversight, product or data question
  2. Lesson 2

    Module 3

    1 lesson · 30 min

    1. Locked.Jurisdictions, the protocol and the ethics committee30 min · Locked

      On completion you will be able to

      • State the EU and UK framework dates and identify the EC recommendation paper correctly
      • Distinguish decentralised trial conduct from decentralised manufacture of IMPs
      • Identify the two final FDA guidances with their status, dates and dockets
      • Draft the protocol description and justification of a decentralised element against section 3.2
      • Prepare the IRB/IEC-facing description of a decentralised methodology
      • Reason from the current framework rather than from pandemic-era flexibilities
  3. Lesson 3

    Module 4

    1 lesson · 30 min

    1. Locked.Remote informed consent and eConsent design30 min · Locked

      On completion you will be able to

      • Specify how the investigator will assure identity in remote consent and what must be pre-specified
      • Design a consent process with a feasible paper or in-person alternative for participants who prefer it
      • Draft the disclosure of data use and of parties with access to personal information
      • Determine the consent or permission basis for secondary use of data region by region
      • Apply Annex 1 computerised-system expectations to an eConsent platform
  4. Lesson 4

    Module 5

    1 lesson · 30 min

    1. Locked.Remote visits, usual clinical practice and investigator oversight30 min · Locked

      On completion you will be able to

      • Choose and justify a level of investigator oversight for a decentralised activity
      • Classify an activity by healthcare professionals as requiring or not requiring protocol knowledge and apply the correct arrangements
      • Specify certified-copy and data-sharing arrangements for externally generated records
      • Define the documentation of a telehealth visit, including source record and performer
      • Explain why moving an activity off site does not reduce investigator responsibility
  5. Lesson 5

    Module 6

    1 lesson · 30 min

    1. Locked.Home nursing, mobile units and service-provider oversight30 min · Locked

      On completion you will be able to

      • Identify who decides on and who oversees a sponsor-arranged service provider
      • Assess a provider's suitability for a given trial against stated criteria
      • Design the safety information flow from a home visit to the investigator
      • Specify the personal information each provider needs and the safeguard for each disclosure
      • Identify licensure and scope-of-practice questions and who must resolve them
  6. Lesson 6

    Module 7

    1 lesson · 30 min

    1. Locked.Direct-to-participant investigational product supply and accountability30 min · Locked

      On completion you will be able to

      • Distinguish investigator-arranged from sponsor-arranged shipment and state what changes
      • Address each of the section 2.3.1 shipping considerations for a given design
      • Assess a product's suitability for direct-to-participant supply against section 3.6.1
      • Configure shipment so that it starts only after investigator authorisation
      • Design blinding protection and accountability through a decentralised supply chain
      • Determine when existing pharmacy documentation suffices
  7. Lesson 7

    Module 8

    1 lesson · 30 min

    1. Locked.Digital health technologies and digital endpoints30 min · Locked

      On completion you will be able to

      • Apply the data acquisition tool consequences to a wearable
      • Identify which evidentiary question an evidence package leaves unanswered
      • Specify a digital endpoint and the evidence needed to support it
      • Design DHT alert handling that gives the investigator usable information
      • Plan control of vendor firmware or algorithm changes during a trial
  8. Lesson 8

    Module 9

    1 lesson · 30 min

    1. Locked.ePRO, eCOA and moving instruments from paper to screen30 min · Locked

      On completion you will be able to

      • Select an ePRO/eCOA instrument appropriate to a population and endpoint
      • Classify a paper-to-screen migration by extent of change and specify proportionate equivalence evidence
      • Design diary administration rules with justification
      • Ensure timely investigator access to ePRO data affecting eligibility, treatment or safety without unblinding
      • Identify the analysis consequences of a mid-study instrument change
  9. Lesson 9

    Module 10

    1 lesson · 30 min

    1. Locked.Data flow, remote source access and oversight architecture30 min · Locked

      On completion you will be able to

      • Draw a data flow identifying every originator, transfer and control point
      • Identify the source record for each data element and confirm it is defined before the trial starts
      • Determine the depth of sponsor access to RWD a use case requires, proportionate to criticality
      • Specify data-sharing agreements, inspection access and linkage rules
      • Design remote monitoring with read-only source access and its preconditions
      • Design sponsor oversight across multiple service providers
  10. Lesson 10

    Module 11

    1 lesson · 30 min

    1. Locked.Privacy, equity and jurisdiction30 min · Locked

      On completion you will be able to

      • Identify every point at which personal information reaches a party it would not reach in a conventional trial, with the safeguard
      • Explain why pseudonymised data remain personal data
      • Assess a design for equity in both directions and propose an alternative pathway
      • Identify licensure and cross-jurisdiction questions and who must resolve them
      • Assess breach risk for DHT and RWD data and specify mitigation
  11. Lesson 11

    Module 12

    1 lesson · 30 min

    1. Locked.Risk assessment and integrated case30 min · Locked

      On completion you will be able to

      • Conduct a proportionate risk assessment of a trial's decentralised elements
      • Select controls proportionate to likelihood, detectability and impact
      • Integrate the course into a justified decentralisation proposal
      • Identify the elements to drop first and explain why
      • Recommend against an element that is not justified and document the reasoning
  12. Lesson 12

    Module 2

    1 lesson · 30 min

    1. Locked.ICH E6(R3) Annex 2, section by section30 min · Locked

      On completion you will be able to

      • Reproduce the section structure of Annex 2
      • State the status and dates of the E6(R3) Principles and Annex 1 and of Annex 2 accurately
      • Locate the governing provision for a described situation in the Principles, Annex 1 or Annex 2
      • Determine which ICH text applied to a trial on a given date in the EU
      • Explain how proportionality operates across Annex 2

Assessment

How the exam works

The exam is closed-book and multiple choice. Each attempt draws a fresh form to the domain weights above, so no two attempts are the same paper and no answer key circulates. The pass mark is 70% and is fixed — there is no curve, no quota and no adjustment by cohort.

Scoring is immediate. Pass, and every item is reviewed with the option you chose, the correct option and its rationale. If you do not pass, you see your overall score and your score per domain (smaller domains are grouped together); which items you missed, and their answers, are held back so your resit is still a real assessment. A failed attempt may be retaken after 90 days. The wait exists so a retake is a second attempt at the material rather than a second attempt at remembering the paper.

The exam opens once you have marked every lesson of the course complete. Forms are assembled to the blueprint above or not at all: where a domain cannot yet be sampled to that standard, the exam declines to start rather than issue an unbalanced paper. Your material and progress are never affected, and there is no time limit on when you sit.

Passing candidates are issued a certificate with a verification code, valid for 3 years from the date of the pass. Anyone can check that code on our public verification page without an account and without contacting us. To renew, pass the current examination again: renewal opens 180 days before the certificate expires, and a pass issues a renewed certificate valid for a further 3 years from that date.

Certifying authority

Signed by Dr. Diana Nieves Castro, MD

CASRAI’s certification programme is academically and medically directed by Dr. Diana Nieves Castro, MD, Programme Director, who sets the syllabus and blueprint for this credential and signs every certificate issued under it.

CASRAI has maintained the terminology and reporting standards of research administration for over a decade. It assumed leadership of the CRediT contributor-roles taxonomy in 2014 and carried it through to adoption as ANSI/NISO Z39.104-2022, now in use by publishers, funders and institutions worldwide. This examination is drawn from that body of work.

What the credential certifies: that its holder passed the CASRAI examination for this course on the date shown, scored against the blueprint and pass mark published above. It is valid for 3 years, and anyone can check it from the verification code on its face.

Common questions

Decentralized Clinical Trials Certification (DCTP): common questions

What are decentralized elements in clinical trials?

FDA's final guidance describes decentralized elements as trial-related activities that occur remotely, at locations convenient for trial participants. Its examples include telehealth visits with trial personnel, in-home visits with remote trial personnel and visits with local health care providers. The DCTP course starts by sorting each activity in a protocol into at, or away from, the investigator's location.

What is a decentralized clinical trial and how does it work?

FDA uses "decentralized clinical trial" for a clinical trial that includes decentralized elements, so some trial-related activities take place remotely rather than at the trial site. ICH E6(R3) Annex 2 covers decentralized clinical trials alongside pragmatic trials and trials that incorporate real-world data. The DCTP course covers how investigators and sponsors oversee each remote activity.

What is the difference between ICH E6 R2 and R3?

ICH E6(R3) is the current revision of the ICH Good Clinical Practice guideline. In the EU, its Principles and Annex 1 came into effect on 23 July 2025. Annex 2, which covers decentralized and pragmatic trial designs and real-world data, was adopted by ICH on 3 June 2026 and will come into effect in the EU on 15 January 2027. DCTP is written against E6(R3).

Is there FDA guidance on decentralized clinical trials?

Yes. FDA's final guidance "Conducting Clinical Trials With Decentralized Elements" was issued in September 2024 under docket FDA-2022-D-2870. It gives recommendations to sponsors, investigators and other interested parties on using decentralized elements in clinical trials. The DCTP course covers it alongside ICH E6(R3) Annex 2 and EU and UK rules.

How does the DCTP exam work, and what does it cost?

DCTP costs US$279, a one-time card payment through Stripe checkout, and course access does not expire. After you complete all 12 lessons, you take an online exam of 75 multiple-choice items with four options each, which you must finish within 4 hours of starting; the pass mark is 70%. If you do not pass, you can retake it after 90 days.

How do I get a CRA certification?

DCTP is not a clinical research associate (CRA) credential and does not replace one. It is an examined CASRAI credential for people who run or oversee trials with remote, home-based or digital elements. To be eligible, you confirm at checkout that you have working knowledge of ICH E6(R3) GCP and either 24 months in clinical research, at a research site or on an ethics committee, or a CASRAI clinical Professional credential plus 12 months' experience.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →